Insider · CIK 0001721411
Eyal Rubin
Files at PLX (Protalix BioTherapeutics, Inc.), NSRX (Nasus Pharma Ltd). First filing -, latest -.
In brief
Eyal Rubin files SEC Form 4 as CFO at PLX (Protalix BioTherapeutics, Inc.), and also at NSRX (Nasus Pharma Ltd). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Eyal Rubin has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 23, 2024 | PLX Protalix BioTherapeutics, Inc. | AGrant or award Common Stockindirect: By Trust | +90,909 | - | - | 660,909 | Nov 5, 2024 |
Questions about Eyal Rubin
Answered from the filings on this page, as of the latest one.
Is Eyal Rubin buying or selling?
Eyal Rubin has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Eyal Rubin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Eyal Rubin has 0.
Where does Eyal Rubin file Form 4?
Eyal Rubin has filed Form 4 at PLX (Protalix BioTherapeutics, Inc.) as Sr. VP and CFO; NSRX (Nasus Pharma Ltd) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.